EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes.
Viruses
; 16(8)2024 Aug 14.
Article
in En
| MEDLINE
| ID: mdl-39205268
ABSTRACT
The acquisition or reactivation of Epstein-Barr virus (EBV) after allogeneic Hematopoietic Stem Cell Transplant (HSCT) can be associated with complications including the development of post-transplant lymphoproliferative disorder (PTLD), which is associated with significant morbidity and mortality. A number of risk factors for PTLD have been defined, including T-cell depletion, and approaches to monitoring EBV, especially in high-risk patients, with the use of preemptive therapy upon viral activation have been described. Newer therapies for the preemption or treatment of PTLD, such as EBV-specific cytotoxic T-cells, hold promise. Further studies to help define risks, diagnosis, and treatment of EBV-related complications are needed in this at-risk population.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Transplantation, Homologous
/
Virus Activation
/
Herpesvirus 4, Human
/
Hematopoietic Stem Cell Transplantation
/
Epstein-Barr Virus Infections
/
Lymphoproliferative Disorders
Limits:
Humans
Language:
En
Journal:
Viruses
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: